Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD in Systemic Light Chain Amyloidosis
NCT07215494Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Dec 2025
- Primary completion
- Sep 2029
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of daratumumab, bortezomib, cyclophosphamide and dexamethasone in light-chain amyloidosis, sponsored by Peking University First Hospital. Primary endpoints: Organ Response Rates at 2 years, Progression-Free Survival at 2 years and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
daratumumabbortezomibcyclophosphamidedexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on NCT07215494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215494.